Full-Time

Translational Medical Oncologist

Precede Biosciences

Precede Biosciences

51-200 employees

Epigenomic liquid biopsy for cancer.

Compensation Overview

$275k - $380k/yr

Boston, MA, USA

Hybrid

Category
Biology & Biotech (2)
,
Requirements
  • M.D. or M.D./Ph.D. in cancer biology, molecular biology, genomics, or a related field
  • Extensive experience in translational oncology research and biomarker development
  • Deep expertise in cancer biology, including signaling pathways, regulatory networks, tumor evolution, and mechanisms of therapeutic resistance
  • Experience applying multi-omic approaches—including epigenomics—to translational research or diagnostic development
  • Demonstrated success building and leading collaborative research programs with academic and industry partners
  • Strong publication record and experience presenting research at major scientific meetings
  • Proven ability to translate complex biological insights into clinically relevant hypotheses and applications
  • Strategic thinker with strong leadership capabilities and a bias toward action in a fast-moving scientific environment
Responsibilities
  • Partner with the Chief Scientific Officer, Chief Executive Officer and scientific leadership to define and execute Precede’s translational science strategy across oncology and other disease areas
  • Identify and prioritize key biological questions that unlock new applications for blood-based epigenomic diagnostics
  • Develop indication strategies and guide the discovery of novel epigenomic biomarkers for disease detection, monitoring, and therapeutic response
  • Translate insights from cancer epigenomic pathways and regulatory networks into clinically actionable hypotheses and diagnostic strategies
  • With Translational Science leads, present Precede’s platform and translational capabilities to academic and biopharma partners
  • Lead and oversee Precede’s portfolio of collaborations, ensuring scientific rigor and strategic alignment with company objectives
  • Build and maintain strong relationships with leading academic investigators and key opinion leaders in oncology and epigenomics
  • Drive the design and execution of collaborative research studies that expand scientific understanding and inform internal assay development
  • Develop and execute a publication and scientific communication strategy, including peer-reviewed manuscripts, conference presentations, and scientific abstracts
  • Interpret multi-omic datasets generated through collaborative studies and translate findings into actionable biological and clinical insights
  • Inform the clinical strategy and intended use for new diagnostic tests derived from Precede’s epigenomic platform
  • Guide biomarker discovery, validation, and integration into assay development and product pipelines
  • Support algorithm development and cutoff determination through the integration of orthogonal biological and clinical datasets
  • Ensure translational insights inform assay optimization, clinical validation strategies, and product positioning
  • Build, lead, and mentor a high-performing translational science organization
  • Establish strategic priorities, goals, and operating processes for translational research programs
  • Ensure strong alignment across translational science, computational biology, assay development, regulatory, and business development teams
  • Foster a collaborative and innovative scientific culture that supports rapid discovery and execution
  • Represent Precede Biosciences at major scientific conferences and industry forums
  • Contribute to the scientific visibility of the company through publications and external collaborations
  • Maintain deep awareness of emerging discoveries and technologies in epigenomics, cancer biology, and biomarker development
  • Establish strong working relationships across computational biology, assay development, operations, regulatory, and business development
  • Ensure alignment between translational strategy, platform capabilities, and company objectives
Desired Qualifications
  • None

Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.

Company Size

51-200

Company Stage

Series B

Total Funding

$140.5M

Headquarters

Boston, Massachusetts

Founded

2021

Your Connections

People at Precede Biosciences who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Precede Bio Insight opens pharma collaborations for longitudinal biomarker studies.
  • AACR 2026 data support breast, prostate, and lung cancer use cases.
  • Target and pathway readouts fit radioligands, ADCs, and endocrine therapies.

What critics are saying

  • RUO status delays reimbursement and clinical revenue.
  • Liquid biopsy must match tissue biomarkers, or confidence collapses.
  • Large diagnostics incumbents can outspend and out-distribute Precede quickly.

What makes Precede Biosciences unique

  • Genome-wide epigenomic liquid biopsy from 1 mL plasma, not single-gene testing.
  • Infers promoter, enhancer, expression, pathway activity, and cell-state biology.
  • Built from Dana-Farber research and supports RUO plus clinical products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Stock Options

Company Equity

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Mentorship Program

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-3%

2 year growth

-3%
Benzinga
Jan 12th, 2026
Precede Biosciences raises $83.5M to scale precision diagnostics platform for next-generation cancer therapies

Precede Biosciences, a precision diagnostics company focused on enabling next-generation precision medicines, has secured $83.5 million in total financing, comprising $63.5 million in Series B equity and a $20 million non-dilutive credit facility. The Boston-based company's platform supports development and clinical use of cancer therapies where target expression and pathway activity serve as defining biomarkers, including drug-, radio-, and immune-conjugates. The funding will scale operations to meet growing demand from developers of these precision medicines. New investors include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital and Alexandria Venture Investments, alongside existing backers. The expanded investor base brings expertise in diagnostics commercialisation and health system adoption.

Southwest Daily News
Oct 21st, 2023
Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine

Precede Biosciences unveils groundbreaking clinical data for its pioneering Liquid Biopsy platform at ESMO 2023 and simultaneously publishes in Nature Medicine.

Forbes
Oct 11th, 2023
Innovationrx: Israel Makes Up 8% Of Teva'S Global Production

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.Teva is focused on ensuring the safety of its employees and doesn’t expect the war to have a “meaningful impact” on its business. AFP via Getty ImagesM ore than 2,250 people have been killed since the Palestinian militant group Hamas launched an assault on Israel over the weekend. Tel Aviv-based Teva, one of the largest generic drugmakers in the world, told Forbes that the $14.9 billion company (2022 sales) has been focused on ensuring the safety of its employees and doesn’t expect the war to have a “meaningful impact” on its business. Israel accounts for around 2% of Teva’s global revenues and 8% of total global production.“We are deeply saddened by the unprecedented, horrific, and brutal attacks on Israeli civilians, including women and children,” spokesperson Kelley Dougherty said in a statement. “As an Israeli company we condemn this appalling assault and Teva stands with Israel in this time of great loss and challenge.” Dougherty said the company has backup manufacturing locations for key products

GlobeNewswire
Oct 5th, 2023
Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy Platform

Unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of individual genes and...